Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.
We describe 4 cases of zygomycosis that occurred after prolonged use of voriconazole in severely immunocompromised patients with hematologic disease. An invasive infection was present in 3 patients who died soon after the diagnosis at 12, 13, and 45 days. Physicians should be mindful of this potential risk after treatment with voriconazole.
Vigouroux
Stéphane
S
Service d'Hematologie Clinique, CHU Hotel Dieu, Nantes, France. vigouroux.st@wanadoo.fr
Morin
Odile
O
Moreau
Philippe
P
Méchinaud
Françoise
F
Morineau
Nadine
N
Mahé
Béatrice
B
Chevallier
Patrice
P
Guillaume
Thierry
T
Dubruille
Viviane
V
Harousseau
Jean-Luc
JL
Milpied
Noël
N
D020095:Absidia / Q000302:isolation & purification; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009091:Mucormycosis / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality / Q000601:surgery; D011743:Pyrimidines / Q000627:therapeutic use*; D020103:Rhizomucor / Q000302:isolation & purification; D012233:Rhizopus / Q000302:isolation & purification; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole